Grayscale Funds Trust Grayscale Bitcoin Adopters ETF (ARCA: BCOR)

Dernières nouvelles pour Grayscale Funds Trust Grayscale Bitcoin Adopters ETF (ARCA:BCOR)

Blucora

Technology

Consumer Cyclical

Communication Services

Financial Services

Other

Industrials

Energy

Healthcare

Utilities

Under normal circumstances, the Fund will invest at least 80 percent of its net assets (including investment borrowings) in the constituents that comprise the Index and in other instruments that have economic characteristics and provide investment exposure similar to the component securities of the Index. Other instruments that have economic characteristics and provide investment exposure similar to the component securities of the Index include depositary receipts (such as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs)). The Fund invests in equity securities (e.g., common stock) and depositary receipts of companies included in the Index. The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The Index follows a rules-based methodology.

Microstrategy Inc

Tesla, Inc.

Metaplanet Inc

Nexon Co Ltd

Mercadolibre Inc

Aker Asa

Galaxy Digital Inc

Coinbase Global, Inc.

Alliance Resource Partners Lp

Block, Inc

Grayscale Bitcoin Adopters ETF

Grayscale Funds Trust Grayscale Bitcoin Adopters ETF

With corporate adoption of Bitcoin picking up pace, Grayscale is betting that investors want in—not by way of the cryptocurrency itself, but through the companies that are adopting it. The crypto asset manager has unveiled the Grayscale Bitcoin Adopters ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NYSE">BCOR</a>), an <a href="https://www.benzinga.com/etfs">innovative new fund </a>that tracks publicly traded companies with Bitcoin as part of their corporate treasuries.
Unlike spot Bitcoin ETFs that track the price of the asset, BCOR is constructed on the Indxx Bitcoin Adopters Index, a carefully curated basket of international companies that have incorporated Bitcoin as a financial strategy, not merely a fad. The fund started with 29 holdings, $1.01 million in assets under management, and an expense ratio of 0.59%.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45143330/ai-hypersonics-24-billion-market-portfolio-manager-gives-a-peek-inside-gcads-bet-on-drone-warfar">AI, Hypersonics, $24 Billion Market: Portfolio Manager Gives A Peek Inside GCAD&#8217;s Bet On Drone Warfare Dominance</a>
Some of BCOR&#8217;s top holdings are MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and Nexon Co Ltd. (OTCPK: NEXOF)—names that have hit the headlines with their Bitcoin treasury maneuvers. Grayscale does not view this as a fad, but rather a paradigm shift.
<a href="https://www.globenewswire.com/news-release/2025/04/30/3071376/0/en/Grayscale-Launches-Grayscale-Bitcoin-Adopters-ETF-Ticker-BCOR.html">According </a>to David LaValle, global head of ETFs at Grayscale, BCOR provides investors with a new way to participate in the growing trend of corporate Bitcoin treasury adoption without needing to hold Bitcoin directly.
Nevertheless, it&#8217;s not a pure-play <a href="https://www.benzinga.com/topic/bitcoin">Bitcoin investment</a>. The performance of the fund will depend not only on Bitcoin prices but on how markets price the companies that are betting on it—adding complexity (and possibly volatility) to the pitch.
With eight ETFs now available in the U.S., Grayscale continues to probe the waters between traditional finance and digital assets. And with BCOR, it&#8217;s asking investors not only to bet on the future of Bitcoin but on who&#8217;s investing in it now.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/04/45085447/qqq-vs-cqqq-which-tech-etf-should-you-bet-on-now-as-ai-boom-meets-u-s-china-trade-thaw">QQQ Vs CQQQ: Which Tech ETF Should You Bet On Now As AI Boom Meets U.S.-China Trade Thaw?</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

New ETFs

ETFs

BCOR

MELI

MSTR

NEXOF

TSLA

New Grayscale ETF Lets You Invest In Bitcoin, Without The Coin

<a href="https://pro.benzinga.com/?utm_source=insights"> Benzinga Pro data,</a> Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) reported Q3 sales of $171.70 million. Earnings fell to a loss of $21.84 million, resulting in a 155.4% decrease from last quarter. Blucora earned $39.42 million, and sales totaled $256.88 million in Q2.
<h3>Why Is ROIC Significant?</h3>
Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q3, Blucora posted an ROIC of 4.66%.
Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. 
ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Blucora is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Blucora, the positive return on invested capital ratio of 4.66% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Analyst Predictions</h3>
Blucora reported Q3 earnings per share at $-0.2/share, which did not meet analyst predictions of $-0.16/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Blucora's Return on Invested Capital Insights

<h3>Gainers</h3>
<ul>
<li>Abiomed, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abmd#NASDAQ">ABMD</a>) shares surged 49.9% to settle at $377.82 on Tuesday after Johnson &amp; Johnson announced it <a href="https://www.benzinga.com/quote/ABMD/analyst-ratings"> will acquire the company </a>. Also, the company reported better-than-expected Q2 adjusted EPS results.</li>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sonn#NASDAQ">SONN</a>) gained 46.6% to close at $2.83. Sonnet BioTherapeutics recently announced an agreement with Janssen for the evaluation of three Sonnet product candidates.</li>
<li>NLS Pharmaceutics AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nlsp#NASDAQ">NLSP</a>) gained 44% to settle at $0.74. NLS Pharmaceutics was granted FDA Orpha Drug Designation for Quilience (Mazindol) for the treatment of idiopathic hypersomnia.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) jumped 34.7% to close at $1.71.</li>
<li>Safe-T Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfet#NASDAQ">SFET</a>) shares gained 30.7% to close at $0.3921 on Tuesday as the company said its privacy application reached over 5,000,000 downloads.</li>
<li>Aravive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arav#NASDAQ">ARAV</a>) gained 30.5% to close at $1.71.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>) jumped 25.1% to settle at $2.49.</li>
<li>Mill City Ventures III, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcvt#NASDAQ">MCVT</a>) gained 24.1% to close at $2.73.</li>
<li>IDEX Biometrics ASA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idba#NASDAQ">IDBA</a>) climbed 23% to close at $7.27.</li>
<li>Harsco Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hsc#NYSE">HSC</a>) climbed 22.5% to close at $6.48 after the company reported better-than-expected Q3 sales results and raised FY22 adjusted EPS guidance.</li>
<li>Cabaletta Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/caba#NASDAQ">CABA</a>) gained 21.9% to close at $2.06.</li>
<li>Baosheng Media Group Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/baos#NASDAQ">BAOS</a>) rose 21.2% to close at $1.05.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aneb#NASDAQ">ANEB</a>) surged 20.3% to settle at $2.90.</li>
<li>Humanigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hgen#NASDAQ">HGEN</a>) gained 19.9% to settle at $0.1680.</li>
<li>NantHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nh#NASDAQ">NH</a>) jumped 19.6% to close at $0.3886.</li>
<li>Tarena International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tedu#NASDAQ">TEDU</a>) gained 18.3% to settle at $5.49.</li>
<li>Leju Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/leju#NYSE">LEJU</a>) rose 18.2% to close at $1.56.</li>
<li>IronNet, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/irnt#NYSE">IRNT</a>) gained 17.4% to close at $0.8338. IronNet announced receipt of continued listing standard notice from NYSE.</li>
<li>Pharming Group N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phar#NASDAQ">PHAR</a>) gained 17.2% to close at $11.40.</li>
<li>Ambow Education Holding Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ambo#NYSE">AMBO</a>) surged 16.8% to close at $0.3038.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reto#NASDAQ">RETO</a>) climbed 16.4% to close at $0.6399.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) gained 14.6% to close at $3.38 after Loop Capital initiated coverage on the stock with a Buy rating and a $18 price target.</li>
<li>Harmony Biosciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrmy#NASDAQ">HRMY</a>) rose 14% to settle at $59.26 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Community Health Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cyh#NYSE">CYH</a>) gained 13.6% to close at $3.26. Community Health Systems recently posted a Q3 loss of $0.52 per share.</li>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) jumped 13.4% to settle at $15.73 after the company reported better-than-expected Q3 sales results.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) gained 12.9% to close at $15.28 after JP Morgan upgraded the stock from Underweight to Neutral and announced a $20 price target.</li>
<li>Zai Lab Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zlab#NASDAQ">ZLAB</a>) shares jumped 12.3% to close at $25.02. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>Kiniksa Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knsa#NASDAQ">KNSA</a>) climbed 12.1% to close at $12.80 after the company posted a profit for the third quarter.</li>
<li>Uber Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) rose 12% to close at $29.75 after the company reported better-than-expected Q3 sales results and Q3 monthly active platform consumers of 124 million, up 14% year over year.</li>
<li>Kanzhun Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bz#NASDAQ">BZ</a>) jumped 11.7% to close at $12.21. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>H World Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htht#NASDAQ">HTHT</a>) shares climbed 10.8% to close at $30.00.</li>
<li>MINISO Group Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mnso#NYSE">MNSO</a>) rose 10.4% to close at $5.63.</li>
<li>IDEXX Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxx#NASDAQ">IDXX</a>) surged 9.8% to settle at $394.93 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>RLX Technology Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rlx#NYSE">RLX</a>) rose 9.6% to close at $1.37 after declining over 7% on Monday.</li>
<li>Hologic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) rose 9.3% to close at $74.13 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Trip.com Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcom#NASDAQ">TCOM</a>) shares gained 8.4% to settle at $24.54 amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>Lattice Semiconductor Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lscc#NASDAQ">LSCC</a>) gained 8.4% to close at $52.58 after the company reported better-than-expected Q3 EPS and sales results. The company also issued Q4 sales guidance above analyst estimates.</li>
<li>Aeglea BioTherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agle#NASDAQ">AGLE</a>) climbed 7.8% to close at $1.11. Wells Fargo recently upgraded the stock from Equal-Weight to Overweight and raised its price target from $1.5 to $2.</li>
<li>Cyxtera Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyxt#NASDAQ">CYXT</a>) gained 6.6% to close at $2.58.</li>
<li>Blucora, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcor#NASDAQ">BCOR</a>) gained 6.1% to close at $23.37 after the company reported better-than-expected Q3 sales results and announced it sold TaxAct for $720 million in cash.</li>
<li>iQIYI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iq#NASDAQ">IQ</a>) rose 5.5% to close at $2.13. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>) gained 5.3% to close at $5.73 after the company reported better-than-expected Q3 EPS and sales results and raised FY22 revenue guidance.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) gained 3.5% to close at $15.15 in sympathy with Uber, which reported better-than-expected Q3 sales results and Q3 monthly active platform consumers of 124 million, up 14% year over year.</li>
</ul>
&nbsp;
<h3>
Losers</h3>
<ul>
<li>Varonis Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrns#NASDAQ">VRNS</a>) shares fell 35.5% to close at $17.27 on Tuesday after the company reported worse-than-expected Q3 results.</li>
<li>Satixfy Communications Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/satx#NYSE">SATX</a>) dipped 29.4% to close at $11.51.</li>
<li>China Liberal Education Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cleu#NASDAQ">CLEU</a>) fell 27.4% to settle at $1.14.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) shares fell 25.2% to close at $0.8001 after jumping over 63% on Monday.</li>
<li>Catalent, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctlt#NYSE">CTLT</a>) fell 24.7% to close at $49.53 after the company reported worse-than-expected Q1 EPS and sales results and issued FY23 sales guidance below estimates.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) fell 22.9% to close at $9.94.</li>
<li>LMF Acquisition Opportunities, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icu#NASDAQ">ICU</a>) fell 22.1% to close at $8.48.</li>
<li>Coeptis Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coep#NASDAQ">COEP</a>) dropped 21.4% to close at $5.11. Coeptis Therapeutics announced closing of business combination with Bull Horn Holdings Corp.</li>
<li>Instil Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/til#NASDAQ">TIL</a>) fell 20.3% to settle at $2.63. Instil Bio voluntarily paused enrollment of its ongoing clinical trials. Cowen &amp; Co. downgraded Instil Bio from Outperform to Market Perform.</li>
<li>Solaris Oilfield Infrastructure, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soi#NYSE">SOI</a>) fell 19.8% to settle at $10.92 following downbeat quarterly sales.</li>
<li>Vyant Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vynt#NASDAQ">VYNT</a>) fell 18.8% to close at $0.3799 after the company announced a one-for-five reverse stock split.</li>
<li>Starry Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stry#NYSE">STRY</a>) dropped 18.6% to close at $0.18. Citigroup recently downgraded the stock from Neutral to Sell and lowered its price target from $3.75 to $0.25.</li>
<li>TETRA Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tti#NYSE">TTI</a>) declined 18.2% to close at $4.04 following weak quarterly results.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) declined 18% to close at $0.9099. Argo Blockchain shares dipped around 44% on Monday after the company announced it believes its previously announced non-binding LOI with a strategic investor to raise $27 million via a subscription for ordinary shares will no longer be conssumated.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) dropped 17.9% to settle at $9.02.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdio#NASDAQ">CDIO</a>) fell 17.3% to close at $2.35.</li>
<li>Clearwater Paper Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clw#NYSE">CLW</a>) declined 16.8% to close at $37.00 following Q3 results. RBC Capital downgraded Clearwater Paper from Outperform to Sector Perform.</li>
<li>Zebra Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zbra#NASDAQ">ZBRA</a>) dropped 15.9% to close at $238.30 after the company reported worse-than-expected Q3 EPS and sales results. The company also issued Q4 EPS guidance below analyst estimates.</li>
<li>Myriad Genetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>) fell 15.6% to close at $17.50 following downbeat Q3 results.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gt#NASDAQ">GT</a>) fell 14.9% to close at $10.81 after the company reported worse-than-expected Q3 earnings.</li>
<li>Transcat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trns#NASDAQ">TRNS</a>) dropped 12.8% to close at $72.13 following Q2 results.</li>
<li>Paragon 28, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fna#NYSE">FNA</a>) fell 12.8% to close at $17.41. Paragon 28 filed for mixed shelf of up to $100 million.</li>
<li>Uxin Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uxin#NASDAQ">UXIN</a>) dropped 12.6% to close at $3.60.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) fell 11.2% to close at $11.86 after the company reported Q3 earnings results and issued FY22 guidance.</li>
<li>OrthoPediatrics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) fell 10.7% to close at $37.96 after the company issued FY22 revenue guidance below estimates.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) declined 10.3% to settle at $3.40. Nikola recently announced a hydrogen supply collaboration with Keystate.</li>
<li>Harmonic Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlit#NASDAQ">HLIT</a>) dropped 10.2% to close at $13.88 following Q3 results.</li>
<li>SeqLL Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sql#NASDAQ">SQL</a>) fell 10.1% to close at $0.5290.</li>
<li>Evolent Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) declined 9.1% to close at $28.93. Truist Securities initiated coverage on Evolent Health with a Hold rating and announced a price target of $33.</li>
<li>Ecolab Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) dropped 9% to close at $142.98 after the company reported worse-than-expected Q3 EPS results.</li>
<li>TopBuild Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bld#NYSE">BLD</a>) dropped 7.6% to close at $157.18 following Q3 results.</li>
<li>Kforce Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kfrc#NASDAQ">KFRC</a>) fell 7.5% to close at $58.53 after reporting Q3 results.</li>
<li>Avis Budget Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/car#NASDAQ">CAR</a>) fell 6.7% to close at $220.52 following Q3 results.</li>
<li>Sealed Air Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/see#NYSE">SEE</a>) dipped 6.7% to close at $44.42 after the company announced it will acquire Liquibox for $1.15 billion. The company also reported worse-than-expected Q3 sales.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) dropped 6.4% to close at $3.49.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bw#NYSE">BW</a>) fell 4.8% to close at $4.34.</li>
<li>Stryker Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) fell 4% to close at $220.09 after the company reported worse-than-expected Q3 results and issued 2022 guidance below estimates.</li>
</ul>

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABMD

ACOR

AGLE

AMBO

ANEB

ARAV

ARBK

ATAI

BAOS

BCRX

CABA

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CLEU

COEP

CTLT

CVNA

CYXT

HGEN

HLIT

HOLX

HRMY

HTHT

ICPT

IDBA

IDXX

IRNT

KFRC

KIDS

KNSA

LEJU

LSCC

LYFT

MCVT

MNSO

MYGN

NKLA

NLSP

PERF

PHAR

RETO

SatixFy Communications Ltd. Ordinary Share

SATX

SFET

SLNA

SNOA

SOFI

SONN

STRY

TCOM

TEDU

TRNS

UBER

UXIN

VRNS

VYNT

ZBRA

ZLAB

Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday

U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.
<ul>
<li>Abiomed, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abmd#NASDAQ">ABMD</a>) shares surged 49.9% to settle at $377.82 on Tuesday after Johnson &amp; Johnson announced it will acquire the company. Also, the company reported better-than-expected Q2 adjusted EPS results.</li>
<li>Harsco Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hsc#NYSE">HSC</a>) climbed 22.5% to close at $6.48 after the company reported better-than-expected Q3 sales results and raised FY22 adjusted EPS guidance.</li>
<li>Harmony Biosciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrmy#NASDAQ">HRMY</a>) rose 14% to settle at $59.26 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) jumped 13.4% to settle at $15.73 after the company reported better-than-expected Q3 sales results.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) gained 12.9% to close at $15.28 after JP Morgan upgraded the stock from Underweight to Neutral and announced a $20 price target.</li>
<li>Zai Lab Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zlab#NASDAQ">ZLAB</a>) shares jumped 12.3% to close at $25.02. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>Companhia Paranaense de Energia &ndash; COPEL (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elp#NYSE">ELP</a>) gained 12.2% to settle at $7.93.</li>
<li>Kiniksa Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knsa#NASDAQ">KNSA</a>) climbed 12.1% to close at $12.80 after the company posted a profit for the third quarter.</li>
<li>Uber Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) rose 12% to close at $29.75 after the company reported better-than-expected Q3 sales results and Q3 monthly active platform consumers of 124 million, up 14% year over year.</li>
<li>Kanzhun Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bz#NASDAQ">BZ</a>) jumped 11.7% to close at $12.21. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>H World Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htht#NASDAQ">HTHT</a>) shares climbed 10.8% to close at $30.00.</li>
<li>Weibo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wb#NASDAQ">WB</a>) gained 10.1% to settle at $12.46.</li>
<li>IDEXX Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxx#NASDAQ">IDXX</a>) surged 9.8% to settle at $394.93 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Sony Group Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sony#NYSE">SONY</a>) rose 9.7% to close at $74.01 after the company reported better-than-expected Q2 EPS and sales results.</li>
<li>Rumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rum#NASDAQ">RUM</a>) gained 9.5% to close at $13.30.</li>
<li>Hologic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) rose 9.3% to close at $74.13 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Autohome Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/athm#NYSE">ATHM</a>) jumped 9% to settle at $28.46.</li>
<li>Rambus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmbs#NASDAQ">RMBS</a>) surged 8.8% to close at $32.83 following Q3 results.</li>
<li>Trip.com Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcom#NASDAQ">TCOM</a>) shares gained 8.4% to settle at $24.54 amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>Lattice Semiconductor Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lscc#NASDAQ">LSCC</a>) gained 8.4% to close at $52.58 after the company reported better-than-expected Q3 EPS and sales results. The company also issued Q4 sales guidance above analyst estimates.</li>
<li>Gartner, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/it#NYSE">IT</a>) jumped 7.6% to close at $325.00 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Blucora, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcor#NASDAQ">BCOR</a>) gained 6.1% to close at $23.37 after the company reported better-than-expected Q3 sales results and announced it sold TaxAct for $720 million in cash.</li>
<li>iQIYI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iq#NASDAQ">IQ</a>) rose 5.5% to close at $2.13. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) gained 3.5% to close at $15.15 in sympathy with Uber, which reported better-than-expected Q3 sales results and Q3 monthly active platform consumers of 124 million, up 14% year over year.</li>
</ul>

ATHM

RMBS

Sony Group Corporation American Depositary Shares

SONY

Gartner, Sony, Uber And Other Big Gainers From Tuesday

Barrington Research analyst Alexander Paris maintains Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) with a Outperform and raises the price target from $25 to $30.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Blucora, Raises Price Target to $30

<h3>Gainers</h3>
<ul>
<li>Safe-T Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfet#NASDAQ">SFET</a>) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.</li>
<li>Abiomed, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abmd#NASDAQ">ABMD</a>) shares jumped 50.4% to $379.01 after Johnson &amp; Johnson announced it will acquire the company. Also, the company reported better-than-expected Q2 adjusted EPS results.</li>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sonn#NASDAQ">SONN</a>) surged 35.7% to $2.62. Sonnet BioTherapeutics recently announced an agreement with Janssen for the evaluation of three Sonnet product candidates.</li>
<li>IDEX Biometrics ASA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idba#NASDAQ">IDBA</a>) gained 28.8% to $7.61.</li>
<li>Aravive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arav#NASDAQ">ARAV</a>) climbed 26.3% to $1.65.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reto#NASDAQ">RETO</a>) gained 23.7% to $0.6801.</li>
<li>Ambow Education Holding Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ambo#NYSE">AMBO</a>) climbed 18.9% to $0.3094.</li>
<li>MINISO Group Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mnso#NYSE">MNSO</a>) gained 17.3% to $5.98.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) surged 17% to $3.47 after Loop Capital initiated coverage on the stock with a Buy rating and a $18 price target.</li>
<li>Harsco Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hsc#NYSE">HSC</a>) rose 16.6% to $6.17 after the company reported better-than-expected Q3 sales results and raised FY22 adjusted EPS guidance.</li>
<li>Uber Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) gained 16% to $30.82 after the company reported better-than-expected Q3 sales results and Q3 monthly active platform consumers of 124 million, up 14% year over year.</li>
<li>Cyxtera Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyxt#NASDAQ">CYXT</a>) jumped 15.5% to $2.7950.</li>
<li>Aeglea BioTherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agle#NASDAQ">AGLE</a>) surged 15.4% to $1.1803. Wells Fargo recently upgraded the stock from Equal-Weight to Overweight and raised its price target from $1.5 to $2.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) rose 15.2% to $15.58 after JP Morgan upgraded the stock from Underweight to Neutral and announced a $20 price target.</li>
<li>SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>) gained 15% to $6.26 after the company reported better-than-expected Q3 EPS and sales results and raised FY22 revenue guidance.</li>
<li>Zai Lab Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zlab#NASDAQ">ZLAB</a>) shares gained 13.8% to $25.38. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>Blucora, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcor#NASDAQ">BCOR</a>) rose 13.2% to $24.95 after the company reported better-than-expected Q3 sales results and announced it sold TaxAct for $720 million in cash.</li>
<li>Kiniksa Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knsa#NASDAQ">KNSA</a>) gained 12.8% to $12.89 after the company posted a profit for the third quarter.</li>
<li>RLX Technology Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rlx#NYSE">RLX</a>) rose 12% to $1.40 after declining over 7% on Monday.</li>
<li>GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) shares rose 11.8% to $9.65 after dipping more than 10% on Monday.</li>
<li>Kanzhun Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bz#NASDAQ">BZ</a>) climbed 10% to $12.02. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>H World Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htht#NASDAQ">HTHT</a>) shares rose 9.8% to $29.74.</li>
<li>Trip.com Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcom#NASDAQ">TCOM</a>) shares rose 9.8% to $24.85 amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>iQIYI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iq#NASDAQ">IQ</a>) rose 9.7% to $2.2150. Shares of Chinese companies traded higher amid unconfirmed rumors suggesting a committee was exploring ways to ease China&#39;s &#39;Zero COVID&#39; policy. A Chinese Foreign Ministry spokesman said he was unaware of a committee.</li>
<li>IDEXX Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxx#NASDAQ">IDXX</a>) gained 8.7% to $390.89 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Lattice Semiconductor Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lscc#NASDAQ">LSCC</a>) climbed 8.5% to $52.63 after the company reported better-than-expected Q3 EPS and sales results. The company also issued Q4 sales guidance above analyst estimates.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) gained 8.5% to $15.90 in sympathy with Uber, which reported better-than-expected Q3 sales results and Q3 monthly active platform consumers of 124 million, up 14% year over year.</li>
<li>Hologic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) rose 8.4% to $73.47 after the company reported better-than-expected Q3 EPS and sales results.</li>
</ul>
&nbsp;
<h3>Losers</h3>
<ul>
<li>Varonis Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrns#NASDAQ">VRNS</a>) shares dipped 32.5% to $18.08 after the company reported worse-than-expected Q3 results.</li>
<li>Catalent, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctlt#NYSE">CTLT</a>) fell 26.5% to $48.34 after the company reported worse-than-expected Q1 EPS and sales results and issued FY23 sales guidance below estimates.</li>
<li>Coeptis Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coep#NASDAQ">COEP</a>) dropped 22.1% to $5.07. Coeptis Therapeutics announced closing of business combination with Bull Horn Holdings Corp.</li>
<li>Myriad Genetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>) fell 19.1% to $16.78 following downbeat Q3 results.</li>
<li>Satixfy Communications Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/satx#NYSE">SATX</a>) dipped 19% to $13.20.</li>
<li>LMF Acquisition Opportunities, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icu#NASDAQ">ICU</a>) fell 18.8% to $8.84.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdio#NASDAQ">CDIO</a>) fell 18.3% to $2.32.</li>
<li>Instil Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/til#NASDAQ">TIL</a>) fell 18.3% to $2.6900. Instil Bio voluntarily paused enrollment of its ongoing clinical trials. Cowen &amp; Co. downgraded Instil Bio from Outperform to Market Perform.</li>
<li>Ever-Glory International Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evk#NASDAQ">EVK</a>) dropped 17.3% to $0.8101.</li>
<li>TETRA Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tti#NYSE">TTI</a>) declined 17.2% to $4.09 following weak quarterly results.</li>
<li>Solaris Oilfield Infrastructure, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soi#NYSE">SOI</a>) dropped 17.2% to $11.23 following downbeat quarterly sales.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) fell 16.2% to $0.93. Argo Blockchain shares dipped around 44% on Monday after the company announced it believes its previously announced non-binding LOI with a strategic investor to raise $27 million via a subscription for ordinary shares will no longer be conssumated.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) fell 16.2% to $10.80.</li>
<li>Transcat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trns#NASDAQ">TRNS</a>) dropped 15.8% to $69.64 following Q2 results.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gt#NASDAQ">GT</a>) fell 15.4% to $10.75 after the company reported worse-than-expected Q3 earnings.</li>
<li>Zebra Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zbra#NASDAQ">ZBRA</a>) dropped 15.4% to $239.65 after the company reported worse-than-expected Q3 EPS and sales results. The company also issued Q4 EPS guidance below analyst estimates.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) fell 14.6% to $11.40 after the company reported Q3 earnings results and issued FY22 guidance.</li>
<li>Clearwater Paper Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clw#NYSE">CLW</a>) declined 12.8% to $38.75 following Q3 results. RBC Capital downgraded Clearwater Paper from Outperform to Sector Perform.</li>
<li>OrthoPediatrics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) fell 12.1% to $37.35 after the company issued FY22 revenue guidance below estimates.</li>
<li>Stryve Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snax#NASDAQ">SNAX</a>) dropped 11.7% to $0.2471.</li>
<li>Avis Budget Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/car#NASDAQ">CAR</a>) fell 9.9% to $213.03 following Q3 results.</li>
<li>TopBuild Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bld#NYSE">BLD</a>) dropped 9.7% to $153.66 following Q3 results.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) shares fell 9.5% to $0.9679 after jumping over 63% on Monday.</li>
<li>Evolent Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) declined 9.4% to $28.82. Truist Securities initiated coverage on Evolent Health with a Hold rating and announced a price target of $33.</li>
<li>Harmonic Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlit#NASDAQ">HLIT</a>) dropped 9.3% to $14.01 following Q3 results.</li>
<li>Sealed Air Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/see#NYSE">SEE</a>) dipped 9.2% to $43.26 after the company announced it will acquire Liquibox for $1.15 billion. The company also reported worse-than-expected Q3 sales.</li>
<li>Ecolab Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) dropped 8.8% to $143.25 after the company reported worse-than-expected Q3 EPS results.</li>
<li>SeqLL Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sql#NASDAQ">SQL</a>) fell 8.1% to $0.5412.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bw#NYSE">BW</a>) declined 8.1% to $4.19.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) dropped 8% to $3.43.</li>
<li>Kforce Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kfrc#NASDAQ">KFRC</a>) fell 7.8% to $58.33 after reporting Q3 results.</li>
<li>Stryker Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) fell 4.3% to $219.50 after the company reported worse-than-expected Q3 results and issued 2022 guidance below estimates.</li>
</ul>

Intraday Update

SNAX

Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session

WIIM

Blucora shares are trading higher after the company reported better-than-expected Q3 sales results and announced it sold TaxAct for $720 million in cash.

Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) reported its Q3 earnings results on Tuesday, November 1, 2022 at 06:30 AM.
Here&#39;s what investors need to know about the announcement.
<h3>Earnings</h3>
Blucora missed estimated earnings by 25.0%, reporting an EPS of $-0.2 versus an estimate of $-0.16.
Revenue was down $2.48 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.05 which was followed by a 5.16% drop in the share price the next day.
Here&#39;s a look at Blucora&#39;s past performance:
&nbsp;
<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
<th>Q3 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.04</td>
<td>1.27</td>
<td>-0.45</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>1.06</td>
<td>-0.29</td>
<td>-0.26</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>260.85M</td>
<td>325.09M</td>
<td>166.23M</td>
<td>165.88M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>256.88M</td>
<td>307.55M</td>
<td>178.33M</td>
<td>174.17M</td>
</tr>
</tbody>
</table>
To track all earnings releases for Blucora <a href="https://www.benzinga.com/quote/BCOR/earnings">visit their earnings calendar here.</a>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Blucora: Q3 Earnings Insights

Blucora Sells Tax Software Business, TaxAct For $720M In Cash

Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) reported adj quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 23.08 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $171.70 million which beat the analyst consensus estimate of $165.14 million by 3.97 percent. This is a 1.42 percent decrease over sales of $174.17 million the same period last year.

Blucora Q3 Adj EPS $(0.20) Misses $(0.16) Estimate, Sales $171.70M Beat $165.14M Estimate

&nbsp;Avantax&reg;, a leader in tax-focused financial planning, continued its strong recruiting results during the&nbsp;second quarter&nbsp;of 2022, with approximately&nbsp;$514 million&nbsp;in newly recruited total client assets. Avantax recruited more than&nbsp;$1 billion&nbsp;in total client assets during the first half of 2022, surpassing the firm&#39;s full-year 2021 performance.

Avantax Reports Newly Recruited Total Client Assets Exceeding $1B In H1 2022

&nbsp;
Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM.
Here&#39;s what investors need to know about the announcement.
<h3>Earnings</h3>
Blucora missed estimated earnings by 4.81%, reporting an EPS of $0.99 versus an estimate of $1.04.
Revenue was up $2.57 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.21 which was followed by a 3.06% increase in the share price the next day.
Here&#39;s a look at Blucora&#39;s past performance:
&nbsp;
<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
<th>Q3 2021</th>
<th>Q2 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.27</td>
<td>-0.45</td>
<td>-0.37</td>
<td>1.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.06</td>
<td>-0.29</td>
<td>-0.26</td>
<td>1.28</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>325.09M</td>
<td>166.23M</td>
<td>165.88M</td>
<td>252.00M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>307.55M</td>
<td>178.33M</td>
<td>174.17M</td>
<td>254.31M</td>
</tr>
</tbody>
</table>
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Blucora management provided guidance for FY 2022, expecting earnings between $1.71 and $1.9 per share.
To track all earnings releases for Blucora <a href="https://www.benzinga.com/quote/BCOR/earnings">visit their earnings calendar here.</a>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Recap: Blucora Q2 Earnings

Blucora: Q2 Earnings Insights

Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) reported quarterly earnings of $0.99 per share which missed the analyst consensus estimate of $1.04 by 4.81 percent. This is a 22.66 percent decrease over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $256.88 million which missed the analyst consensus estimate of $260.85 million by 1.52 percent. This is a 1.01 percent increase over sales of $254.31 million the same period last year.

Blucora Q2 EPS $0.99 Misses $1.04 Estimate, Sales $256.88M Miss $260.85M Estimate

Upgrades

Downgrades

Initiation

AFRM

BROS

CDEV

CIVI

CTMX

DOCN

DUOL

FATE

FFWM

FSLY

GIII

HDSN

KRUS

LULU

LUNG

MGNX

MYPS

NEWR

ONEM

PIPR

PNFP

PODD

QRVO

SILK

TMHC

TROW

UPST

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Cantor Fitzgerald analyst Josh Siegler initiates coverage on Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) with a Overweight rating and announces Price Target of $22.

Cantor Fitzgerald Initiates Coverage On Blucora with Overweight Rating, Announces Price Target of $22

<a href="https://pro.benzinga.com/?utm_source=insights">According to Benzinga Pro,</a> during Q1, Blucora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOR#NASDAQ">BCOR</a>) earned $34.62 million, a 246.11% increase from the preceding quarter. Blucora also posted a total of $307.55 million in sales, a 72.46% increase since Q4. Blucora collected $178.33 million in revenue during Q4, but reported earnings showed a $23.69 million loss. 
<h3>Why Is ROCE Significant?</h3>
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Blucora posted an ROCE of 0.1%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. 
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Blucora is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Blucora, the positive return on capital employed ratio of 0.1% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Upcoming Earnings Estimate</h3>
Blucora reported Q1 earnings per share at $1.06/share, which did not meet analyst predictions of $1.27/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Looking Into Blucora's Return On Capital Employed

<h3>Gainers</h3>
<ul>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) jumped 40.3% to close at $30.69 after better than expected Q1 earnings and 2022 guidance.</li>
<li>Aclarion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acon#NASDAQ">ACON</a>) jumped 36.6% to settle at $2.35 after declining over 5% on Tuesday. The company had its IPO on April 22.</li>
<li>Alaunos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrt#NASDAQ">TCRT</a>) jumped 36% to settle at $0.7547 after jumping around 13% on Tuesday.</li>
<li>Bright Health Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhg#NYSE">BHG</a>) gained 33.3% to close at $2.24 after the company reported better-than-expected Q1 sales results and reaffirmed FY22 guidance.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) climbed 31.2% to settle at $30.69 after the company reported better-than-expected Q3 EPS and sales results and raised Q4 guidance.</li>
<li>Livent Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lthm#NYSE">LTHM</a>) gained 30.3% to close at $28.55 after the company reported better-than-expected Q1 results and raised FY22 guidance.</li>
<li>AIkido Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aiki#NASDAQ">AIKI</a>) jumped 30.1% to settle at $0.4622. AIkido Pharma reported strategic investment in social communications platform, Discord.</li>
<li>BlueLinx Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bxc#NYSE">BXC</a>) gained 28.5% to close at $98.39 after the company reported better-than-expected Q1 EPS and sales results and increased its share buyback to $100 million.</li>
<li>Superior Industries International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sup#NYSE">SUP</a>) shares jumped 28% to close at $4.11 following better-than-expected Q1 results.</li>
<li>CarParts.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prts#NASDAQ">PRTS</a>) shares gained 27.2% to close at $8.65 after the company reported better-than-expected Q1 EPS and sales results.</li>
<li>Locafy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcfy#NASDAQ">LCFY</a>) rose 26.3% to close at $1.49.</li>
<li>eHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ehth#NASDAQ">EHTH</a>) jumped 24.9% to settle at $10.35 after the company reported better-than-expected Q1 sales results.</li>
<li>China Liberal Education Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cleu#NASDAQ">CLEU</a>) gained 23.5% to close at $2.1850. China Liberal Education won project bid from Fuzhou Melbourne Polytechnic for construction of smart language training experimental classrooms with cloud for $150,000.</li>
<li>Kimball International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kbal#NASDAQ">KBAL</a>) surged 22.8% to close at $9.39 after the company reported better-than-expected Q3 sales results and adjusted EPS results were higher year over year.</li>
<li>Sharps Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stss#NASDAQ">STSS</a>) gained 22.7% to close at $1.57 after climbing around 6% on Tuesday.</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) rose 22.4% to settle at $34.67.</li>
<li>Gogoro Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ggr#NASDAQ">GGR</a>) jumped 20.5% to close at $7.17.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) gained 20.5% to settle at $3.23.</li>
<li>Vivint Smart Home, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vvnt#NYSE">VVNT</a>) rose 19.6% to close at $6.47 after the company reported better-than-expected Q1 sales results and reaffirmed FY22 sales guidance.</li>
<li>W&amp;T Offshore, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wti#NYSE">WTI</a>) gained 19.2% to close at $5.90 after the company reported better-than-expected Q1 EPS and sales results.</li>
<li>Tenon Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnon#NASDAQ">TNON</a>) surged 19.2% to settle at $34.56.</li>
<li>Global Industrial Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gic#NYSE">GIC</a>) jumped 18.8% to close at $36.20 following strong Q1 earnings.</li>
<li>Clene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clnn#NASDAQ">CLNN</a>) rose 17.6% to settle at $3.14.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eose#NASDAQ">EOSE</a>) gained 17.6% to close at $2.54.</li>
<li>Summit Midstream Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smlp#NYSE">SMLP</a>) rose 17.3% to close at $20.66 following Q1 results.</li>
<li>Chegg, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chgg#NYSE">CHGG</a>) gained 17.1% to close at $20.39 as the stock rebounded after falling following its Q1 earnings report.</li>
<li>Cloopen Group Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/raas#NYSE">RAAS</a>) surged 16.8% to close at $0.80.</li>
<li>Meta Data Limited ADS (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aiu#NYSE">AIU</a>) jumped 16.7% to close at $1.54.</li>
<li>JE Cleantech Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jcse#NASDAQ">JCSE</a>) gained 16.7% to settle at $5.80.</li>
<li>Powell Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/powl#NASDAQ">POWL</a>) rose 16.3% to close at $23.04 after the company reported better-than-expected Q2 EPS and sales results.</li>
<li>Imperial Petroleum Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impp#NASDAQ">IMPP</a>) gained 15.5% to settle at $1.04.</li>
<li>U.S. Energy Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/useg#NASDAQ">USEG</a>) jumped 15.4% to settle at $4.50. U.S. Energy announced plans to acquire Bolt-On assets for $1 million.</li>
<li>Zosano Pharma Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zsan#NASDAQ">ZSAN</a>) rose 15.3% to close at $1.96. Zosano Pharma recently announced it has suspended its M207 program and implemented a workforce reduction impacting 40% of remaining employees.</li>
<li>Huadi International Group Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hudi#NASDAQ">HUDI</a>) gained 15.2% to close at $26.31.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) surged 15.1% to close at $4.04.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) jumped 15% to settle at $14.51. The company recently completed a SPAC merger deal last week and began trading on Thursday.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) surged 15% to close at $9.98.</li>
<li>HashiCorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcp#NASDAQ">HCP</a>) rose 14.4% to settle at $54.54.</li>
<li>A10 Networks, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aten#NYSE">ATEN</a>) gained 14.3% to close at $16.78 after the company reported better-than-expected Q1 adjusted EPS and sales results.</li>
<li>Paycom Software, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/payc#NYSE">PAYC</a>) jumped 13.8% to settle at $328.20 after the company reported better-than-expected Q1 EPS and sales results and issued FY22 and Q2 sales guidance above analyst estimates.</li>
<li>Biora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prog#NASDAQ">PROG</a>) rose 13.6% to close at $0.9743.</li>
<li>Generac Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gnrc#NYSE">GNRC</a>) jumped 11.8% to close at $261.78 after the company reported better-than-expected Q1 EPS and sales results. The company also raised its FY22 sales growth guidance.</li>
<li>Brickell Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbi#NASDAQ">BBI</a>) gained 11.8% to close at $0.26 after the company announced the sale of sofpironium bromide to Botanix Pharmaceuticals for $9 million in upfront and potential near-term regulatory milestone payments. The company is also eligible to receive additional success-based regulatory and sales milestone payments of up to $168 million.</li>
<li>The Scotts Miracle-Gro Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>) gained 10% to close at $116.57. Scotts Miracle-Gro announced record second-quarter sales in its U.S. consumer segment driven by continued support from its major retail partners.</li>
<li>Starbucks Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbux#NASDAQ">SBUX</a>) gained 9.8% to close at $81.64 as the company reported second-quarter revenue of $7.64 billion, which was up 15% year-over-year. The quarterly revenue was a second-quarter record for the company and came in ahead of a consensus estimate of $7.6 billion.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Connect Biopharma Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cntb#NASDAQ">CNTB</a>) shares tumbled 57.7% to close at $0.8202 after the company announced week 12 top-line results from its Phase 2 CBP-307 trial in patients with moderate-to-severe ulcerative colitis.</li>
<li>Kezar Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kzr#NASDAQ">KZR</a>) dipped 43.5% to close at $6.96 after the company reported topline results from the PRESIDIO Phase 2 trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM), chronic inflammatory diseases of muscle.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) shares tumbled 43.1% to close at $1.56 on Wednesday after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations. The company reported Q1 sales of $94.6 million, down 33% Y/Y, missing the consensus of $128.37 million.</li>
<li>Blue Water Vaccines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bwv#NASDAQ">BWV</a>) fell 32.7% to settle at $4.34. Blue Water Vaccines S-1 showed registration for 2.4 million share common stock offering via selling shareholders.</li>
<li>Tupperware Brands Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tup#NYSE">TUP</a>) fell 32.2% to settle at $12.15 after the company reported worse-than-expected Q1 results and withdrew its FY22 guidance.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) fell 29.9% to close at $21.56 after the company reported Q1 earnings results and issued Q2 sales guidance below analyst estimates.</li>
<li>The Andersons, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ande#NASDAQ">ANDE</a>) dropped 26.8% to close at $38.20 after the company reported Q1 earnings results.</li>
<li>Shineco, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sisi#NASDAQ">SISI</a>) fell 24.4% to settle at $1.80.</li>
<li>Quad/Graphics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/quad#NYSE">QUAD</a>) fell 23.5% to close at $4.78 following Q1 results.</li>
<li>IAMGOLD Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iag#NYSE">IAG</a>) fell 23.3% to close at $2.14 following Q1 results. The company also named Maryse B&eacute;langer as Interim President and CEO.</li>
<li>Clovis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clvs#NASDAQ">CLVS</a>) declined 20% to close at $1.68 after the company reported worse-than-expected Q1 EPS and sales results.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ost#NASDAQ">OST</a>) fell 20% to close at $3.80 on post-IPO volatility.</li>
<li>Cyngn Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) dipped 19.3% to close at $3.17.</li>
<li>Harvard Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hbio#NASDAQ">HBIO</a>) fell 18.1% to close at $4.63 after the company reported Q1 earnings results.</li>
<li>MacroGenics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgnx#NASDAQ">MGNX</a>) fell 16.9% to close at $6.44 following Q1 results.</li>
<li>Blucora, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcor#NASDAQ">BCOR</a>) fell 16.6% to close at $17.32 after the company reported worse-than-expected Q1 EPS and sales results and issued FY22 adjusted EPS and sales guidance below estimates.</li>
<li>Allena Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alna#NASDAQ">ALNA</a>) dipped 16.4% to close at $0.1416.</li>
<li>T Stamp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idai#NASDAQ">IDAI</a>) dropped 16% to close at $2.47.</li>
<li>Blackboxstocks Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blbx#NASDAQ">BLBX</a>) fell 15.7% to close at $2.57. The company announced it has completed its platform Integration with E*TRADE allowing users to trade seamlessly through the Blackbox platform.</li>
<li>Arko Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arko#NASDAQ">ARKO</a>) dropped 15.2% to close at $8.12 following Q1 earnings.</li>
<li>Revolve Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvlv#NYSE">RVLV</a>) fell 14.9% to close at $37.01 after the company reported Q1 earnings results.</li>
<li>Infinera Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infn#NASDAQ">INFN</a>) dropped 14.6% to close at $6.74 after the company reported worse-than-expected Q1 adjusted EPS and sales results and issued Q2 sales guidance below analyst estimates.</li>
<li>Cardiovascular Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/csii#NASDAQ">CSII</a>) fell 14.3% to close at $17.26 after reporting weak quarterly sales.</li>
<li>Conduent Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cndt#NASDAQ">CNDT</a>) fell 14.2% to close at $4.65 following Q1 results.</li>
<li>Denny&#39;s Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/denn#NASDAQ">DENN</a>) dipped 13.8% to close at $11.31 after the company reported worse-than-expected Q1 EPS results.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) fell 12.6% to close at $1.60. XORTX Therapeutics shares jumped 59% on Tuesday after the company announced that dosing of human subjects has been initiated in the XRX-OXY-101 bridging pharmacokinetics study.</li>
<li>Brinker International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eat#NYSE">EAT</a>) fell 12.2% to close at $34.65 after the company reported worse-than-expected Q1 EPS and sales results. The company also issued FY22 EPS guidance below analyst estimates.</li>
<li>LL Flooring Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ll#NYSE">LL</a>) fell 12% to close at $13.11 after the company reported worse-than-expected Q1 EPS and sales results.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kymr#NASDAQ">KYMR</a>) dropped 11.4% to close at $22.04. Kymera Therapeutics reported worse-than-expected Q1 EPS and sales results.</li>
<li>LSB Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lxu#NYSE">LXU</a>) slipped 10% to close at $20.53 after the company reported worse-than-expected Q1 results.</li>
<li>Akamai Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akam#NASDAQ">AKAM</a>) fell 9.7% to settle at $102.76 after the company reported worse-than-expected Q1 results.</li>
<li>Johnson Controls International plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jci#NYSE">JCI</a>) fell 8.7% to close at $56.52 after the company cut its FY22 EPS guidance below analyst estimates.</li>
<li>Red Rock Resorts, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rrr#NASDAQ">RRR</a>) fell 7.5% to close at $41.57 following weak quarterly sales.</li>
<li>Herbalife Nutrition Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) shares fell 6.2% to close at $25.85 after the company reported a decline in Q1 EPS results.</li>
<li>Skyworks Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swks#NASDAQ">SWKS</a>) fell 5% to close at $113.53 following Q2 results.</li>
</ul>

Comments

Grayscale Funds Trust Grayscale Bitcoin Adopters ETF

Actualités

Dernières nouvelles pour Grayscale Funds Trust Grayscale Bitcoin Adopters ETF (ARCA:BCOR)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL